Atlas One · Host Biology · Scale 03 — Molecular

RET

Receptor tyrosine kinase; point mutations (C634R in MEN2A, M918T in MEN2B) cause hereditary medullary thyroid carcinoma; RET/PTC fusions in papillary thyroid cancer. Selpercatinib and pralsetinib are approved RET inhibitors in RET-mutant MTC and RET fusion thyroid/NSCLC.

Also known as: RET, RET proto-oncogene, RET kinase, RET/PTC, BCR-ABL-like RET, GDNF receptor, cadherin-related tyrosine kinase

Scale 03 — MolecularScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
ret

RET

Receptor tyrosine kinase; point mutations (C634R in MEN2A, M918T in MEN2B) cause hereditary medullary thyroid carcinoma; RET/PTC fusions in papillary thyroid cancer. Selpercatinib and pralsetinib are approved RET inhibitors in RET-mutant MTC and RET fusion thyroid/NSCLC.

Entry Metadata

FieldValue
IDret
NameRET
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale03-molecular

Cross-Atlas Connections

connects-toKras connects-toMtor connects-toVegf connects-toStat3 connects-toThyroid Cancer connects-toCalcitonin connects-toBraf

Sources